Research Studies

Investigate the effects of short-term treatment (16 weeks) of semaglutide as compared to placebo on intestinal permeability in subjects with T2D.

Participants should be type 2 diabetic and be treated with metformin only. Each participant will complete 7-8 visits. After screening, participants will be given either semaglutide or a placebo and will be asked to self-administer the medication once weekly. Study visits will include blood draws and frequent urine samples. Participants will also be asked to provide a stool sample after screening and at their final in-person visit.

Main Procedures Involved: Blood draw, lactulose mannitol ratio test (urine test), vitals, stool samples, subcutaneous injection of semaglutide or placebo once weekly.

Duration of Participation: 5-6 months